-+ 0.00%
-+ 0.00%
-+ 0.00%
Chinese synthetic biomaterials company Baiyin Biotech announced the completion of Series A financing of over 200 million yuan. L'Oréal Group's investment funds participated. Among them, Wobolian Guangzhou Pharmaceutical Fund and L'Oréal BOLD Fund led the A round; Fuhua Capital, Cornerstone Capital, Xingbo Shenghui, and Junkedanmu participated; Guangxin Fund led the A+ round.
Share
Listen to the news
Baiyin Biotech, a Chinese synthetic biomaterials company, announced the completion of Series A financing of more than 200 million yuan. L'Oréal Group's investment funds participated. Among them, Wobolian Guangzhou Pharmaceutical Fund and L'Oréal BOLD Fund led the A round; Fuhua Capital, Cornerstone Capital, Xingbo Shenghui, and Junkedanmu participated; Guangxin Fund led the A+ round.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending